The association of BMI with risk of recurrence and progression in patients with non-muscle-invasive bladder cancer.
作者信息
Vrieling Alina
机构信息
Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
出版信息
Transl Androl Urol. 2018 Dec;7(Suppl 6):S702-S705. doi: 10.21037/tau.2018.10.17.
Abstract
摘要
相似文献
1
The association of BMI with risk of recurrence and progression in patients with non-muscle-invasive bladder cancer.体重指数与非肌层浸润性膀胱癌患者复发和进展风险的关联。
Transl Androl Urol. 2018 Dec;7(Suppl 6):S702-S705. doi: 10.21037/tau.2018.10.17.
2
No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression.成人 BMI 和糖尿病与非肌层浸润性膀胱癌复发和进展无明确关联。
PLoS One. 2020 Mar 25;15(3):e0229384. doi: 10.1371/journal.pone.0229384. eCollection 2020.
3
Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer.慢性肾脏病作为原发性非肌层浸润性膀胱癌患者复发和病情进展的一个危险因素。
Int J Urol. 2017 Aug;24(8):594-600. doi: 10.1111/iju.13389. Epub 2017 Jul 22.
4
Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.1973 年和 2004/2016 年世界卫生组织分级分类系统在非肌肉浸润性膀胱癌中的预后性能和可重复性：欧洲泌尿外科学会非肌肉浸润性膀胱癌指南小组系统评价。
Eur Urol. 2017 Nov;72(5):801-813. doi: 10.1016/j.eururo.2017.04.015. Epub 2017 Apr 28.
5
Previous Bladder Cancer History in Patients with High-Risk, Non-muscle-invasive Bladder Cancer Correlates with Recurrence and Progression: Implications of Natural History.高危非肌层浸润性膀胱癌患者既往膀胱癌病史与复发及进展的相关性：自然病史的影响
Cancer Res Treat. 2015 Jul;47(3):495-500. doi: 10.4143/crt.2014.050. Epub 2014 Sep 11.
6
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.再次经尿道膀胱肿瘤切除术（re-cTURBT）作为pT1期高级别（HG）疾病复发和进展的风险指标是否有用？一项单中心经验。
Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272.
7
Risk-based Management of Non-muscle Invasive Bladder Cancer: Experience from Tribhuvan University Teaching Hospital.非肌肉浸润性膀胱癌的基于风险的管理：特里布万大学教学医院的经验。
Kathmandu Univ Med J (KUMJ). 2016;14(56):352-356.
8
9
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.EORTC 列线图和风险分组用于预测非肌肉浸润性 Ta-T1 期尿路上皮膀胱癌患者接受 1-3 年卡介苗维持治疗后的复发、进展、疾病特异性和总生存情况。
Eur Urol. 2016 Jan;69(1):60-9. doi: 10.1016/j.eururo.2015.06.045. Epub 2015 Jul 23.
10
Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.非肌肉浸润性膀胱癌患者的复发与进展：包括多色荧光原位杂交分子分级的预后模型
Int J Urol. 2014 Oct;21(10):968-72. doi: 10.1111/iju.12509. Epub 2014 Jun 19.
本文引用的文献
1
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
2
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.多机构 T1G3 非肌层浸润性膀胱癌患者队列中中性粒细胞与淋巴细胞比值的验证。
Clin Genitourin Cancer. 2018 Dec;16(6):445-452. doi: 10.1016/j.clgc.2018.07.003. Epub 2018 Jul 6.
3
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer.体重指数增加与 T1 期膀胱癌患者接受卡介苗免疫治疗的预后较差相关。
World J Urol. 2019 Mar;37(3):507-514. doi: 10.1007/s00345-018-2397-1. Epub 2018 Jul 10.
4
Adipose Tissue-Secreted Factors Alter Bladder Cancer Cell Migration.脂肪组织分泌因子改变膀胱癌细胞迁移。
J Obes. 2018 May 20;2018:9247864. doi: 10.1155/2018/9247864. eCollection 2018.
5
Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis.非肌层浸润性膀胱癌（NMIBC）患者治疗前中性粒细胞与淋巴细胞比值（NLR）的预后作用：一项系统评价和荟萃分析
Urol Oncol. 2018 Sep;36(9):389-399. doi: 10.1016/j.urolonc.2018.05.014. Epub 2018 Jun 6.
6
Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis.体重指数、饮食相关因素与膀胱癌预后：一项系统评价与Meta分析
Bladder Cancer. 2018 Jan 20;4(1):91-112. doi: 10.3233/BLC-170147.
7
Obesity and Cancer: Evidence, Impact, and Future Directions.肥胖与癌症：证据、影响及未来方向。
Clin Chem. 2018 Jan;64(1):154-162. doi: 10.1373/clinchem.2017.277376. Epub 2017 Oct 16.
8
Association of body mass index with bladder cancer risk: a dose-response meta-analysis of prospective cohort studies.体重指数与膀胱癌风险的关联：前瞻性队列研究的剂量反应荟萃分析
Oncotarget. 2017 May 16;8(20):33990-34000. doi: 10.18632/oncotarget.16722.
9
Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation.肥胖与癌症机制：肿瘤微环境与炎症
J Clin Oncol. 2016 Dec 10;34(35):4270-4276. doi: 10.1200/JCO.2016.67.4283. Epub 2016 Nov 7.
10
Obesity and Cancer Mechanisms: Cancer Metabolism.肥胖与癌症机制：癌症代谢
J Clin Oncol. 2016 Dec 10;34(35):4277-4283. doi: 10.1200/JCO.2016.67.9712. Epub 2016 Nov 7.
Zotero 插件